Login to Your Account

Pharma: Other News To Note

Friday, April 26, 2013
• Actavis Inc., of Parsippany, N.J., reached a settlement agreement with Shire plc, of Dublin, Ireland, resolving patent litigation related to Actavis' generic version of INTUNIV (guanfacine hydrochloride) to treat attention deficit hyperactivity disorder. In October 2012, the FDA granted approval of Actavis' abbreviated new drug application.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription